WO2014163150A1 - 内服組成物 - Google Patents

内服組成物 Download PDF

Info

Publication number
WO2014163150A1
WO2014163150A1 PCT/JP2014/059867 JP2014059867W WO2014163150A1 WO 2014163150 A1 WO2014163150 A1 WO 2014163150A1 JP 2014059867 W JP2014059867 W JP 2014059867W WO 2014163150 A1 WO2014163150 A1 WO 2014163150A1
Authority
WO
WIPO (PCT)
Prior art keywords
component
sleep
salt
methylthioadenosine
adenosylmethionine
Prior art date
Application number
PCT/JP2014/059867
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
朋美 瀬古
辰行 翠川
物井　則幸
中村　好孝
智夫 五木田
育子 鎌田
Original Assignee
ライオン株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライオン株式会社 filed Critical ライオン株式会社
Priority to KR1020157024365A priority Critical patent/KR102245628B1/ko
Priority to CN201480018058.7A priority patent/CN105101974B/zh
Priority to JP2015510133A priority patent/JP6214628B2/ja
Publication of WO2014163150A1 publication Critical patent/WO2014163150A1/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/86—Addition of bitterness inhibitors
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Definitions

  • the present invention relates to an internal use composition.
  • the oral composition is taken orally, it is desirable that it does not have an unpleasant taste such as bitterness or astringency when taken.
  • a method of suppressing unpleasant taste such as bitterness As a method of suppressing unpleasant taste such as bitterness, a method of masking bitterness and the like by combining a sweetener such as sucrose with an internal use composition has been conventionally known. However, in such a method, the composition for internal use becomes sweeter than necessary, and the feeling of taking may be worsened, and the effect of suppressing bitterness is not sufficient.
  • Patent Document 1 reports a technique using a bitterness suppressing component such as 5'-adenylic acid (AMP). In such a technique, it has been confirmed that the bitterness of the internal use composition can be suppressed even when it contains a component exhibiting a strong bitter taste such as potassium chloride.
  • a bitterness suppressing component such as 5'-adenylic acid (AMP).
  • AMP 5'-adenylic acid
  • the present inventors have found that methylthioadenosine has an excellent sleep promoting effect.
  • methylthioadenosine has bitterness, and it may be difficult to take an effective amount orally.
  • the present inventors have found that it is difficult to suppress the bitterness caused by methylthioadenosine even with the technique described in Patent Document 1 capable of suppressing the strong bitterness of potassium chloride.
  • An object of the present invention is to provide an internal use composition containing methylthioadenosine with reduced bitterness.
  • the present invention provides the following [1] to [5].
  • component S-adenosylmethionine or a salt thereof
  • the mass ratio of component (A) (as methylthioadenosine) / component (B) (as S-adenosylmethionine) is 0.05 to 1000
  • (A) The internal use composition whose content of a component is 0.1 mass% or more as methylthio adenosine.
  • an object of the present invention is to provide an oral composition containing methylthioadenosine with reduced bitterness.
  • FIG. 1 is a sleep progress diagram showing a general pattern of REM sleep and non-REM sleep.
  • the internal use composition of the present invention comprises (A) component: methylthioadenosine or a salt thereof and (B) component: S-adenosylmethionine or a salt thereof, and the mass ratio of (A) component / (B) component Is 0.05 to 1000, and the content of the component (A) is 0.1% by mass or more.
  • the bitterness when taken orally tends to become remarkable.
  • the present inventors specify that the ratio of the component (A) and the component (B) is a specific ratio even when the content of the component (A) is 0.1% by mass or more. It was found that the bitterness at the time of oral intake can be suppressed by using in combination.
  • the component (A) contained in the internal use composition of the present invention is methylthioadenosine or a salt thereof.
  • methylthioadenosine means 5'-deoxy-5'-methylthioadenosine.
  • 5'-deoxy-5'-methylthioadenosine may be in either the anti-type or the syn-type.
  • the salt of methylthioadenosine is not particularly limited as long as it is a pharmacologically acceptable salt, and can be selected according to the dosage form and the like.
  • Suitable salts of methylthioadenosine include, for example, acid addition salts.
  • the acid addition salt may be either an inorganic acid addition salt or an organic acid addition salt.
  • hydrochloride, sulfate, nitrate, carbonate, phosphate, formate, oxalate, citrate , Ascorbate, methanesulfonate, 1,4-butanedisulfonate, 1,5-pentanesulfonate and p-toluenesulfonate for example, hydrochloride, sulfate, nitrate, carbonate, phosphate, formate, oxalate, citrate , Ascorbate, methanesulfonate, 1,4-butanedisulfonate, 1,5-pentanes
  • the present inventors have found that such methylthioadenosine or a salt thereof has an excellent sleep promoting effect.
  • Non-REM sleep can be determined by polysomnograph analysis (electroencephalogram, electrooculogram, electromyogram). As an electroencephalogram, non-REM sleep can be determined by a decrease in alpha waves (8-13 Hz in humans) and an increase in delta waves (0.5-4.5 Hz in humans). The measured electroencephalogram can also be determined using automatic analysis software such as SleepSign.
  • Non-REM sleep is divided into four stages of layer I, layer II, layer III, and layer IV in the order of shallow sleep according to the depth of sleep.
  • the sleep in which the depth of sleep is in the III layer and the IV layer among the I layer to the IV layer is particularly referred to as “deep sleep”.
  • Methylthioadenosine or a salt thereof has an effect of promoting non-REM sleep, particularly deep sleep, in natural sleep.
  • natural sleep refers to sleep that does not cause loss of direct reflex.
  • Direct reflection is a reflection motion that restores the head to a normal position with respect to the direction of gravity, and is also referred to as bounce reflection.
  • the disappearance of the direct reflex in the mouse or rat can be confirmed, for example, as a state where the mouse or rat placed in the supine position or the dorsal position does not return to the abdominal position within 30 seconds. If a sleeping mouse or rat is placed in a supine or dorsal position and immediately wakes up from sleep or quickly returns to the prone position, the sleep disappears from the positive reflex. There is no sleep. In humans, there is no equivalent of “direct reflection” as defined by animals. However, in humans, a state in which the “direct reflex does not disappear” corresponds to sleep that can be easily awakened, such as waking up immediately when the shoulder is hit, and can be defined as natural sleep.
  • Anesthesia causes the loss of right-angle reflexes against natural sleep. Loss of direct reflex in mice or rats is known as an evaluation index of anesthetic effect. The effect of anesthesia with anesthetics such as pentobarbital or other agents can be assessed by the increase in the number of animals that have lost the right reflex.
  • the origin of the EEG in the frequency band that cannot be seen during sleep without anesthesia or conventional hypnotics is not clear at present, but there is a relationship with the poor awakening of anesthesia or conventional hypnotics Inferred.
  • “Promoting non-REM sleep” means that 1) the state of non-REM sleep is observed for a longer period of time compared to the state to be compared (for example, the state before ingestion of the internal use composition of the present invention), 2) It means that the effect of either deeper non-REM sleep or 3) the smooth transition to non-REM sleep is observed.
  • methylthioadenosine or a salt thereof has an effect of promoting deep sleep in natural sleep.
  • “Deep sleep” means sleep in which the depth of sleep is more than a certain level in humans, and sleep state at a depth of layer III or higher when non-REM sleep is classified into four stages of I to IV layers I mean.
  • the occupancy of the delta wave (0.5-4.5 Hz) to the entire electroencephalogram (0.5-20 Hz) is above a certain level. It is known that the power value is high. Therefore, deep sleep can also be defined as sleep with a high delta power value.
  • the delta power value can be measured using, for example, a polysomnography inspection apparatus, and the “depth of sleep”, which is the sum of sleep depth and time, is obtained by multiplying the delta power value by time. Defined.
  • the delta power value itself is used for mouse and guinea pig sleep, and the time is added to the delta power value.
  • the multiplied value may be the size of deep sleep. “Promoting deep sleep” means that 1) the state of deep sleep is observed for a longer time than the state to be compared (for example, the state before ingestion of the internal use composition of the present invention), 2) It means that the effect of either deeper deep sleep or 3) the smooth transition to deep sleep is observed. That is, in an experimental system using a mouse or guinea pig, the value obtained by multiplying the delta power value by time increases.
  • the origin of the component (A) and the production method thereof are not particularly limited.
  • the component (A) may be methylthioadenosine obtained by chemical synthesis or a salt thereof.
  • the method of chemical synthesis is not particularly limited as long as methylthioadenosine or a salt thereof can be synthesized, and any method may be used.
  • the component (A) may be methylthioadenosine derived from an organism or a salt thereof.
  • methylthioadenosine or a salt thereof can be obtained from S-adenosylmethionine derived from an organism or a salt thereof described later via an intramolecular cyclization reaction of a methionine moiety.
  • one type obtained by a specific origin and production method may be used alone, or two or more types having different origins and production methods may be used in combination.
  • a commercial item may be used for a component.
  • Methylthioadenosine or a salt thereof can be obtained from a supplier such as Sigma-Aldrich.
  • the content of the component (A) is 0.1% by mass or more as methylthioadenosine.
  • the content of the component (A) is 0.1% by mass or more. Even if it exists, the bitterness at the time of oral ingestion can be suppressed.
  • the content of the component (A) is further increased without causing a problem of bitterness when taken orally. be able to.
  • the content of the component (A) in the internal use composition is 0.5% by mass or more, 1% by mass or more, 2% by mass or more, 3% by mass or more, 4% by mass or more, 5% by mass or more as methylthioadenosine, 6% or more, 7% or more, 8% or more, 9% or more, 10% or more, 11% or more, 12% or more, 13% or more, 14% or more, or 15% or more It may be increased to.
  • the upper limit of the content of the component (A) in the internal use composition is not particularly limited, but is usually 50% by mass or less, preferably 20% by mass or less.
  • content of (A) component in an internal use composition is the conversion amount as methylthio adenosine regardless of the origin of (A) component, a manufacturing method, and the kind of methylthio adenosine or its salt. is there.
  • content of (A) component can be measured in a well-known procedure by the liquid chromatography method, for example.
  • the oral composition of the present invention can contain the component (A) at a high content as described above without causing the problem of bitterness when taken orally. Therefore, the internal use composition of this invention can enjoy the effect which (A) component show
  • the content of the component (A) in the internal use composition is preferably 2% by mass or more, more preferably 3% by mass or more, and still more preferably Is 5% by mass or more, and more preferably 10% by mass or more.
  • the component (B) contained in the internal use composition of the present invention is S-adenosylmethionine or a salt thereof.
  • S-adenosylmethionine has a structure in which adenosine and methionine are linked via a methylsulfonyl bond.
  • the optical isomers of methionine include L-form, D-form, and DL-form.
  • methionine in the structure of S-adenosylmethionine may be any of the optical isomers, but is preferably L-form.
  • the salt of S-adenosylmethionine is not particularly limited as long as it is a pharmacologically acceptable salt, and can be selected according to the dosage form and the like.
  • Suitable salts of S-adenosylmethionine include, for example, acid addition salts and halides, and specifically include hydrochloride, sulfate, p-toluenesulfonate (tosylate), sulfuric acid ⁇ p -Toluenesulfonate, methanesulfonic acid, trifluoromethanesulfonic acid, 1,4-butanedisulfonic acid, 1,5-pentanesulfonic acid, phosphate, chloride, bromide and the like. Of these, hydrochloride or tosylate is preferred.
  • the origin of the component (B) and the production method thereof are not particularly limited.
  • the component (B) may be S-adenosylmethionine obtained by chemical synthesis or a salt thereof.
  • the method of chemical synthesis is not particularly limited as long as S-adenosylmethionine or a salt thereof can be synthesized, and any method may be used.
  • the component (B) may be S-adenosylmethionine derived from an organism or a salt thereof.
  • the organism include cells containing S-adenosylmethionine or a salt thereof.
  • the cell containing S-adenosylmethionine or a salt thereof may be a cell originally containing S-adenosylmethionine or a salt thereof.
  • a microbial cell containing S-adenosylmethionine or a salt thereof may be used as the component (B) as it is, or a dry microbial cell obtained by drying the microbial cell may be used as the component (B).
  • S-adenosylmethionine or a salt thereof isolated and purified from the bacterial cells containing S-adenosylmethionine or a salt thereof may be used as component (B).
  • the microbial cells containing S-adenosylmethionine or a salt thereof originally do not contain S-adenosylmethionine or a salt thereof, or contain only a trace amount, but S-adenosylmethionine or It may be a microbial cell that contains S-adenosylmethionine or a salt thereof by producing the salt.
  • Such cells can be obtained, for example, by culturing cells and producing S-adenosylmethionine or a salt thereof in the cells (intracellular).
  • the resulting culture, the culture solution, the cells recovered after the culture, and the dried cells obtained by drying the cells Any of the purified bacterial cells obtained by purifying the body, culture or culture solution, and dried purified bacterial cells obtained by drying the purified bacterial cells may be used as the component (B).
  • the type of microbial cells is not particularly limited, but yeast is preferred.
  • the type of yeast is not particularly limited as long as it produces S-adenosylmethionine or a salt thereof and can be taken orally.
  • yeasts include yeasts of the genus Saccharomyces (Saccharomyces) and yeasts of the genus Shizosaccharomyces (Saccharomyces cerevisiae; budding yeast), Yeast) is preferred.
  • (B) component may be used individually by 1 type obtained by specific origin and a manufacturing method, and may be used in combination of 2 or more types from which an origin and a manufacturing method differ.
  • the component (B) includes chemically synthesized S-adenosylmethionine or a salt thereof, S- A cell containing adenosylmethionine or a salt thereof, a dried product thereof, or a culture thereof is preferable, and chemically synthesized S-adenosylmethionine or a salt thereof, yeast containing S-adenosylmethionine or a salt thereof, a dried product thereof Or a culture thereof.
  • S-adenosylmethionine or a salt thereof can be obtained from a supplier such as Sigma-Aldrich.
  • Commercially available yeast containing S-adenosylmethionine or a salt thereof includes, for example, “SAMe-rich dry yeast (trade name)” manufactured by Mitsubishi Gas Chemical Co., Ltd., “Super Essé ( Product name) ",” Amy (trade name) "manufactured by Iwata Chemical Industry Co., Ltd., and the like.
  • the content of the component (B) is such that the mass ratio of the component (A) to the component (B) (component (A) / component (B)) is in the range of 0.05 to 1000. There is no particular limitation.
  • the content of the component (B) in the oral composition is S-adenosyl regardless of the origin of the component (B), the production method, and the type of S-adenosylmethionine or a salt thereof. It is a conversion amount as methionine.
  • content of (B) component can be measured in a well-known procedure by the liquid chromatography method, for example.
  • the lower limit of the mass ratio of the (A) component and the (B) component promotes sleep while suppressing the bitterness attributed to the (A) component.
  • it is 0.05 or more, preferably 0.1 or more, more preferably 0.2 or more, still more preferably 0.5 or more, and even more preferably.
  • the upper limit of the mass ratio of the component (A) to the component (B) is 1000 or less, preferably 800 or less, from the viewpoint of suppressing the bitterness caused by the component (A). More preferably, it is 600 or less, More preferably, it is 400 or less, More preferably, it is 200 or less.
  • the mass ratio of the component (A) to the component (B) is the mass ratio of the component (A) (as methylthioadenosine) / (B) component (as S-adenosylmethionine).
  • the internal use composition of this invention may further contain components (henceforth "optional component") other than (A) component and (B) component, unless the effect of this invention is impaired essentially.
  • optional components include excipients, disintegrants, binders, lubricants, coating agents, colorants, color formers, flavoring agents, flavoring agents, antioxidants, preservatives, flavoring agents, Pharmacologically acceptable additives such as sour agents, sweeteners, fortifiers, vitamin agents, swelling agents, thickeners, surfactants, solvents and the like can be mentioned.
  • the effects of the present invention and various properties necessary for the preparation are not impaired, and the final product (for example, food and drink, pharmaceuticals, quasi drugs, nutritional supplement products (supplements)) Etc.) can be selected depending on the dosage form.
  • the final product for example, food and drink, pharmaceuticals, quasi drugs, nutritional supplement products (supplements)) Etc.
  • Such pharmacologically acceptable additives may be used alone or in combination of two or more.
  • the internal use composition of the present invention comprises (A) component, (B) component, and a pharmacologically acceptable salt, and the mass of (A) component / (B) component.
  • the ratio is 0.05 to 1000, and the content of the component (A) is 0.1% by mass or more.
  • the internal composition of the present invention may also contain other components that can promote non-REM sleep.
  • other components that can promote non-REM sleep for example, what is called a sleep improving agent, a sleep inducing agent, and the like can be included.
  • a sleep improving agent for example, what is called a sleep improving agent, a sleep inducing agent, and the like can be included.
  • the mixed form with the component of the kind or quantity which produces the loss of specular reflection is excluded.
  • the internal use composition of this invention contains (A) component which has a sleep promotion effect as an active ingredient.
  • the internal use composition of the present invention is preferably an internal use composition for promoting sleep, more preferably an internal use composition for promoting non-REM sleep in natural sleep, and promotion of deep sleep in natural sleep. It is more preferable that the composition is for internal use.
  • the dosage form of the internal use composition of the present invention is, for example, liquid (liquid), syrup (syrup), solid (tablet), capsule (capsule), powder (granule, fine granule), soft capsule (Soft capsule), semi-liquid, cream, and paste.
  • the internal use composition of this invention for food / beverage products, as a dosage form of this food / beverage products, for example, beverages (soft drinks, carbonated drinks, nutrition drinks, powdered drinks, fruit drinks, milk drinks, jelly drinks, etc.) Confectionery (cookies, cakes, gums, candy, tablets, gummies, buns, sheepskins, pudding, jelly, ice cream, sherbet, etc.), processed fishery products (kamaboko, chikuwa, hanpen, etc.), processed livestock products (hamburger, ham, Sausages, winners, cheese, butter, yogurt, fresh cream, margarine, fermented milk, etc.), soups (powdered soup, liquid soup, etc.), staple foods (rice, noodles (dried noodles, raw noodles), bread, cereals, etc.) , Seasonings (mayonnaise, shortening, dressing, sauce, sauce, soy sauce, etc.). Furthermore, the internal use composition of the present invention comprises health food, functional food, health supplement (supplement), nutrition supplement
  • chewable tablets can be mentioned.
  • bitterness is more easily perceived at the time of ingestion, but according to the present invention, bitterness caused by component (A) can be remarkably suppressed, and an effective amount of component (A) A chewable tablet that contains no bitterness when ingested.
  • the internal use composition of the present invention is preferably taken before going to bed.
  • the intake amount of the internal composition of the present invention is not particularly limited as long as the effects of the present invention are not impaired, and can be appropriately adjusted depending on factors such as the age and condition of the living body ingesting the internal composition of the present invention.
  • the lower limit of the intake amount of the internal use composition of the present invention as the intake amount of methylthioadenosine per day (mg / day) is preferably 0.01 mg or more, more preferably 0.1 mg or more, even more preferably.
  • Is 1 mg, and the upper limit thereof is preferably 1000 mg or less, more preferably 500 mg or less, and still more preferably 100 mg or less.
  • the subject of ingestion of the internal composition of the present invention is not particularly limited.
  • people who are ingested may feel sleepy, sleepy when waking up, poor sleep, lack of deep sleep (cannot sleep deeply), bad dreams, and fatigue after sleep.
  • Examples include subjects who are dissatisfied and subjects who feel fatigue and want to improve their subjective sleep feeling.
  • the subject who does not have a special problem can be ingested on a daily basis for the purpose of maintaining good sleep, preventing sleep disorders, and promoting non-REM sleep (particularly deep sleep) in natural sleep.
  • the internal use composition of the present invention can be used as a sleep promoter, preferably a non-REM sleep promoter under natural sleep, more preferably a deep sleep promoter under natural sleep.
  • the time of administration of the sleep promoting agent is not particularly limited, but it is usually administered before going to bed and may be administered between 3 hours before going to bed and before going to bed. More preferably, it is administered between 2 hours before bedtime and during bedtime, more preferably administered between 1 hour before bedtime and during bedtime, and particularly preferably administered 1 hour before bedtime.
  • this sleep promoter can increase the non-REM sleep time during sleep compared with the case where the sleep promoter of this invention is not administered. Specifically, it can be used for the prevention and treatment of sleep quality deterioration due to shortening of non-REM sleep time and / or reduction of depth of non-REM sleep.
  • the internal use composition of the present invention can promote non-REM sleep (especially deep sleep) under natural sleep, and therefore can also be used as a natural sleep inducer. “Inducing natural sleep” refers to inducing sleep without loss of direct reflex. When the internal use composition of the present invention is used as a natural sleep inducer, non-REM sleep (especially deep sleep) can be promoted under natural sleep, so a good sleep pattern is maintained or a disturbed sleep pattern is good It can contribute to recovering to a proper sleep pattern.
  • the present invention also provides a method for suppressing the bitter taste of methylthioadenosine or a salt thereof.
  • bitterness caused by methylthioadenosine or a salt thereof can be suppressed by mixing methylthioadenosine or a salt thereof and S-adenosylmethionine or a salt thereof at a specific mass ratio.
  • the method for suppressing the bitter taste of methylthioadenosine or a salt thereof comprises: (A) component: methylthioadenosine or a salt thereof; (B) component: S-adenosylmethionine or a salt thereof; And a step of mixing so that the mass ratio of (as methylthioadenosine) / (B) component (as S-adenosylmethionine) is 0.05 to 1000.
  • the (A) component and the (B) component are as described above, and the preferable range of the mass ratio of the (A) component / (B) component is also as described above.
  • the component (A) and the component (B) can be mixed so that the mass ratio of the component (A) / the component (B) is 0.05 to 1000.
  • the method is not particularly limited, and a conventionally known mixing method may be used.
  • the bitterness of oral compositions containing methylthioadenosine or a salt thereof when ingested can be remarkably suppressed.
  • the method for suppressing the bitter taste of methylthioadenosine or a salt thereof comprises (A) component: methylthioadenosine or a salt thereof, and (A) component: methylthioadenosine or a salt thereof.
  • the composition of internal use and the component (B): S-adenosylmethionine or a salt thereof, the mass ratio of component (A) (as methylthioadenosine) / component (B) (as S-adenosylmethionine) is 0 And a step of mixing so as to be 05 to 1000.
  • the preferred range of the content of the component (A) in the internal use composition is as described above. According to the present invention, the bitterness attributed to methylthioadenosine or a salt thereof can be remarkably suppressed even in an internal composition in which the content of component (A) is 0.1% by mass or more as methylthioadenosine.
  • Examples 1 to 7 and Comparative Examples 1 to 4 (A) component, (B) component ((B ') component about the comparative example 1), and crystalline cellulose were powder-mixed with the compounding quantity shown in following Table 1, and the composition was obtained. About the obtained composition, the bitterness at the time of oral ingestion and the sleep promoting effect were evaluated according to the following procedure. The results are shown in Table 1.
  • Electroencephalogram and myoelectric electrodes were attached to 8-week-old male C57BL / 6 mice purchased from Japan SLC. After the electrodes were mounted, they were recovered for 10 days in a recovery chamber. Then, it moved to the recording chamber and the cable was connected. Mice that could be discriminated by electroencephalogram using SleepSign (registered trademark) Ver 3.0 (Kissei Comtech Co., Ltd.), an electroencephalogram analysis software, were acclimated for 3 days. Furthermore, the brain waves were then measured for 24 hours, and the administration groups were divided into mice in which sleep / wake rhythm was maintained.
  • As the control solution a 0.5 mass% methylcellulose aqueous solution was used.
  • the above suspension or control solution was forcibly orally administered to each mouse, and the electroencephalogram was recorded for 24 hours.
  • the electroencephalogram was automatically analyzed by SleepSign (registered trademark) Ver 3.0, and the evaluator confirmed the result of the automatic analysis and classified it into sleep stages of wakefulness, REM sleep and non-REM sleep.
  • the total integrated amount (unit: sec) of non-REM sleep time from the start of electroencephalogram measurement to 4 hours later was calculated, and the percentage of non-REM sleep amount at the time of non-administration (baseline) of the same individual was obtained.
  • the average value of percentage was calculated for each administration group, and the sleep promoting effect was evaluated from the average value based on the following evaluation criteria.
  • Methylthioadenosine (MTA) -containing yeast was prepared as follows.
  • Commercially available S-adenosylmethionine-containing yeast culture powder (manufacturer name: Mitsubishi Gas Chemical Co., Ltd., trade name: SAMe-containing dry yeast) was heat-treated at 120 ° C. for 20 minutes.
  • the methylthioadenosine content in the obtained yeast culture was 320 mg
  • the dry weight of the yeast culture (including MTA) was 5000 mg
  • the dry weight of the yeast cultures other than MTA was 4680 mg. That is, the mass ratio of the methylthioadenosine content to the yeast culture was 6.4% by mass.
  • Example 8 a tablet (methylthioadenosine content in 4 tablets: 21 mg) containing the above MTA-containing yeast was prepared. As a sample of Comparative Example 5, a placebo tablet not containing MTA-containing yeast was prepared. Details of each composition are as shown in Table 2.
  • each sample was orally ingested by the same six subjects, and after the subject went to bed, the subject's shoulder was beaten. As a result, it was confirmed for each subject that the subject woke up easily, that is, the sleep after each sample (the sample of Example 8 and Comparative Example 5) was orally ingested by each subject was natural sleep. .
  • the electroencephalogram was analyzed by requesting Sleepwell.
  • the depth of sleep can be known from the delta power value of the electroencephalogram during sleep. The greater the delta power value, the deeper the sleep depth.
  • non-REM sleep appears immediately after going to bed, and REM sleep appears thereafter.
  • the delta power value during non-REM sleep that appeared immediately after going to sleep was taken as the delta power value in the early stage of sleep. .
  • Delta power value varies depending on the individual. Therefore, after ingesting the sample of Example 8 or the sample of Comparative Example 5, the delta power value in the early stage of sleep was measured four times for each subject, and the average value of the four measured values was calculated. For each subject, the change rate (%) of the delta power value after ingestion of the MTA-containing yeast (sample of Example 8) relative to the delta power value after ingestion of the placebo (sample of Comparative Example 5) is calculated by the following equation (1). did.
  • Delta power value change rate (%) ⁇ (Average value of delta power value after sample intake of Example 8) / (Average value of delta power value after sample intake of Comparative Example 5) ⁇ ⁇ 100
  • Table 3 shows the rate of change of the delta power value.
  • the rate of change of the delta power value is an average value of six subjects.
  • Example 3 shows the following.
  • Example 8 in which a tablet containing methylthioadenosine and S-adenosylmethionine at a specific ratio was orally ingested as a sample, the delta power value at the initial stage of sleep was higher than that in Comparative Example 5 in which a placebo tablet was orally ingested. large.
  • the internal use composition of the present invention can sufficiently deepen the non-REM sleep in the early stage of sleep, thereby promoting sleep and inducing good natural sleep.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PCT/JP2014/059867 2013-04-05 2014-04-03 内服組成物 WO2014163150A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR1020157024365A KR102245628B1 (ko) 2013-04-05 2014-04-03 내복 조성물
CN201480018058.7A CN105101974B (zh) 2013-04-05 2014-04-03 内服组合物
JP2015510133A JP6214628B2 (ja) 2013-04-05 2014-04-03 内服組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013079561 2013-04-05
JP2013-079561 2013-04-05

Publications (1)

Publication Number Publication Date
WO2014163150A1 true WO2014163150A1 (ja) 2014-10-09

Family

ID=51658441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/059867 WO2014163150A1 (ja) 2013-04-05 2014-04-03 内服組成物

Country Status (4)

Country Link
JP (1) JP6214628B2 (ko)
KR (1) KR102245628B1 (ko)
CN (1) CN105101974B (ko)
WO (1) WO2014163150A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017057143A (ja) * 2015-09-14 2017-03-23 株式会社Ｎｒｌファーマ 抑うつ状態を改善するための組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5076215A (ko) * 1973-06-27 1975-06-21
JPS56166117A (en) * 1980-04-22 1981-12-21 Bioresearch Srl Antiinflammatory and analgesic adenosine derivative and therapeutical composition containing it as effective component
JP2005514356A (ja) * 2001-11-22 2005-05-19 グノーシス・エツセ・エルレ・エルレ Ｓ−アデノシルメチオニンを含む錠剤の調製方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962034A (en) * 1973-02-01 1976-06-08 Ajinomoto Co., Inc. Method for producing s-adenosylmethionine or methylthioadenosine by yeast
JP2001112474A (ja) * 1999-10-14 2001-04-24 Kansai Tlo Kk 変異型サッカロミセス・セレビシエ
US20030181713A1 (en) * 2002-03-04 2003-09-25 Srirangam Jayaram Kasturi Processes for the synthesis of chloroadenosine and methylthioadenosine
UA88869C2 (ru) * 2002-12-20 2009-12-10 Зе Маклин Хоспитал Корпорейшн Соединения для нормализации цикла сон/бессонница
US7455872B2 (en) 2005-06-20 2008-11-25 Redpoint Bio Corporation Compositions and methods for producing a salty taste in foods or beverages
WO2008090905A1 (ja) * 2007-01-25 2008-07-31 Mitsubishi Gas Chemical Company, Inc. 保存安定性に優れたｓ－アデノシル－ｌ－メチオニン含有乾燥酵母の製造方法、その製造物及びその成型された組成物
US8329208B2 (en) * 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
EP2893931A1 (en) * 2011-03-04 2015-07-15 Lion Corporation Growth hormone secretagogue
JP5989319B2 (ja) * 2011-10-06 2016-09-07 ライオン株式会社 睡眠の質改善剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5076215A (ko) * 1973-06-27 1975-06-21
JPS56166117A (en) * 1980-04-22 1981-12-21 Bioresearch Srl Antiinflammatory and analgesic adenosine derivative and therapeutical composition containing it as effective component
JP2005514356A (ja) * 2001-11-22 2005-05-19 グノーシス・エツセ・エルレ・エルレ Ｓ−アデノシルメチオニンを含む錠剤の調製方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MAGGINI, C. ET AL.: "A Polygraph Evaluation of the Effects of S-Adenosyl-L-Methionine(SAMe) on All-Night Sleep", MONOGRAPHIEN AUS DEM GESAMTGEBIETE DER PSYCHIATRIE, vol. 18, 1978, pages 151 - 169 *
MAKOTO TADENUMA ET AL.: "Seishu no Jukusei ni yoru Komi no Henka ni Kansuru Kenkyu (the 3rd report", JOURNAL OF THE BREWING SOCIETY OF JAPAN, vol. 70, no. 8, 1975, pages 581 - 584 *
MAKOTO TADENUMA ET AL.: "Seishu no Jukusei ni yoru Komi no Henka ni Kansuru Kenkyu (the 4th report)", JOURNAL OF THE BREWING SOCIETY OF JAPAN, vol. 70, no. 8, 1975, pages 585 - 587 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017057143A (ja) * 2015-09-14 2017-03-23 株式会社Ｎｒｌファーマ 抑うつ状態を改善するための組成物

Also Published As

Publication number Publication date
CN105101974A (zh) 2015-11-25
JPWO2014163150A1 (ja) 2017-02-16
JP6214628B2 (ja) 2017-10-18
KR102245628B1 (ko) 2021-04-28
CN105101974B (zh) 2018-07-03
KR20150143430A (ko) 2015-12-23

Similar Documents

Publication Publication Date Title
JP6803915B2 (ja) 睡眠障害改善剤及び睡眠障害の改善方法
JP5210636B2 (ja) 疲労自覚症状改善用組成物
WO2013051728A1 (ja) 睡眠の質改善剤
WO2011096413A1 (ja) 運動機能改善剤
JP5053535B2 (ja) 寝つきまたは寝起き改善用経口剤
JP2011136907A (ja) 持久力向上剤
WO2007066642A1 (ja) 皮膚の乾燥予防または改善用経口剤
JP2008143811A (ja) 脂質代謝促進組成物
JP5922862B2 (ja) ミトコンドリア機能向上剤
JP6214628B2 (ja) 内服組成物
JP2009013143A (ja) 睡眠改善用組成物
JP2008150352A (ja) 睡眠改善剤組成物
JP7162917B2 (ja) 心拍数低下剤
CN111511372A (zh) 预防或减轻非酒精性脂肪肝疾病的组合物
JP2015214518A (ja) 睡眠の質を改善する方法及び睡眠の質の改善用の経口用組成物
JP2009209088A (ja) アスペルロシドまたはその類縁体を含む筋肉増強剤
JP6226962B2 (ja) ノンレム睡眠促進剤、深睡眠促進剤、自然睡眠誘発剤、および睡眠初期デルタパワー向上剤
JP5632162B2 (ja) 経口組成物
JP6294870B2 (ja) 酵母培養物を有効成分とする睡眠促進剤、睡眠促進用内服組成物及び睡眠促進用食品組成物
JP2004131407A (ja) ローヤルゼリー又はその水溶性画分を有効成分とする抗うつ性組成物
JP6329317B1 (ja) 血圧降下用組成物
JP2004292355A (ja) 抗ストレス剤
JP2019156834A (ja) 体質改善剤
JP6434312B2 (ja) 組成物、飲食品、内臓脂肪低減剤、血糖値低減剤、内臓脂肪低減用の飲食品、及び血糖値低減用の飲食品
JP5546854B2 (ja) ダンマラン系トリテルペン類含有飲食品組成物及び呈味改善方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480018058.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14779383

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2015510133

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20157024365

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14779383

Country of ref document: EP

Kind code of ref document: A1